Head and Neck squamous cell carcinoma

• Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma w … Pending
  2025-521437-88-00 4
• IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator … Recruiting
  2025-522500-24-00 5 2026-01-20
• A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck … Recruiting
  2024-517091-38-00 3 2025-11-25
• Transtympanic sodium thiosulfate to prevent cisplatin-related hearing loss, a randomized controlled multicenter phase III trial; The SOUND t … Recruiting
  2023-503313-30-01 5 2025-04-14
• A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants with Head … Recruiting
  2023-508418-40-00 9 2024-12-16
• Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent … Recruiting
  2024-512297-96-01 4 2024-11-26
• Induction treatment of patients with head and neck squamous cell carcinoma using simultaneous chemotherapy and low-dose radiotherapy (iCHRTL … Recruiting
  2024-517480-23-00 4 2022-02-17
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Recruitment ended
  2024-515538-34-00 10 2025-02-27
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Ended
  2023-503418-63-00 4 2023-11-23

Showing 1–9 of 9 trials